- Home
- BTU vs CNTA Comparison
BTU vs CNTA Comparison
Compare BTU & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTU
- CNTA
- Stock Information
- Founded
- BTU 2016
- CNTA 2020
- Country
- BTU United States
- CNTA United Kingdom
- Employees
- BTU N/A
- CNTA N/A
- Industry
- BTU Coal Mining
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- BTU Energy
- CNTA Health Care
- Exchange
- BTU Nasdaq
- CNTA Nasdaq
- Market Cap
- BTU 2.3B
- CNTA 2.2B
- IPO Year
- BTU N/A
- CNTA 2021
- Fundamental
- Price
- BTU $14.63
- CNTA $16.63
- Analyst Decision
- BTU Strong Buy
- CNTA Strong Buy
- Analyst Count
- BTU 5
- CNTA 8
- Target Price
- BTU $27.60
- CNTA $23.00
- AVG Volume (30 Days)
- BTU 3.6M
- CNTA 995.7K
- Earning Date
- BTU 02-06-2025
- CNTA 03-27-2025
- Dividend Yield
- BTU 2.05%
- CNTA N/A
- EPS Growth
- BTU N/A
- CNTA N/A
- EPS
- BTU 2.61
- CNTA N/A
- Revenue
- BTU $4,236,700,000.00
- CNTA $6,853,000.00
- Revenue This Year
- BTU N/A
- CNTA N/A
- Revenue Next Year
- BTU $6.96
- CNTA N/A
- P/E Ratio
- BTU $5.54
- CNTA N/A
- Revenue Growth
- BTU N/A
- CNTA N/A
- 52 Week Low
- BTU $14.61
- CNTA $7.75
- 52 Week High
- BTU $29.94
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- BTU 30.64
- CNTA 48.19
- Support Level
- BTU $14.87
- CNTA $15.50
- Resistance Level
- BTU $17.34
- CNTA $18.55
- Average True Range (ATR)
- BTU 0.88
- CNTA 1.25
- MACD
- BTU -0.13
- CNTA -0.12
- Stochastic Oscillator
- BTU 0.41
- CNTA 31.57
About BTU Peabody Energy Corporation
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. Powder River Basin segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.